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Abstract 
The delivery of drugs into systemic circulation via skin has generated much 
attention during the last decade. Transdermal therapeutic systems propound 
controlled release of active ingredients through the skin and into the systemic 
circulation in a predictive manner. Drugs administered through these systems 
escape first-pass metabolism and maintain a steady state scenario similar to a 
continuous intravenous infusion for up to several days. However, the excellent 
impervious nature of the skin offers the greatest challenge for successful 
delivery of drug molecules by utilizing the concepts of iontophoresis. The 
present review deals with the principles and the recent innovations in the field of 
iontophoretic drug delivery system together with factors affecting the system. 
This delivery system utilizes electric current as a driving force for permeation of 
ionic and non-ionic medications. The rationale behind using this technique is to 
reversibly alter the barrier properties of skin, which could possibly improve the 
penetration of drugs such as proteins, peptides and other macromolecules to 
increase the systemic delivery of high molecular weight compounds with 
controlled input kinetics and minimum inter-subject variability. Although 
iontophoresis seems to be an ideal candidate to overcome the limitations 
associated with the delivery of ionic drugs, further extrapolation of this 
technique is imperative for translational utility and mass human application. 
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Introduction 
Discovering a new medicine is a very expensive and time consuming process. However, 
redesigning the modules and means to transport medicines into the body are more 
lucrative tasks [1]. The design of a dosage form, whether in the form of a tablet, capsule, 
pill, cream, liquid, ointment, aerosol, injectables, suppositories or patch, to deliver the 
exact amount of medicine at right time to the specific target site becomes complicated if 
each medication were not to be delivered in an  optimal and preferred manner to the 
individual patient [2]. Oral ingestion has long been the much convenient and commonly 
employed route of drug delivery. Indeed, for sustained release systems this route had 
received the most attention with respect to research on physiological and drug constraints 
as well as design and testing of products. This is because there is more flexibility in 
dosage form design for the oral route than there is for parenteral route. In contrast 
continuous intravenous infusion is recognized as a superior mode of drug administration 
not only to bypass hepatic “first-pass” metabolism, but also to maintain a constant and 
prolonged drug level in the body [3]. This mode of administration is advantageous to both 
direct entry of drug into the systemic circulation and control of circulating drug levels. 
However, such mode of drug administration entails certain risks and, therefore, 
necessitates hospitalization of  the patients and close medical supervision of 
administration. 
The novel drug delivery systems (NDDS) are being investigated so as to alter the body 
distribution of drug(s) with a view to reduce the toxicity of drug and /or deliver them more 
efficiently to their site of action or to improve therapeutic index. Research soon followed on 
ways the drug levels could be modulated and extended to derive more benefits and lower 
the toxicological risks from the dosage of drug  [4, 5]. Novel delivery systems for non-
traditional routes of administration were subsequently conceived, constructed and put to 
test [6]. In the last three decades a number of modern technologies including targeting 
concepts have emerged for successful delivery of bio-actives. The limitations have been 
overwhelmed by these modern technologies, which are providing effective local as well as 
systemic drug levels at desired sites with improved safety profiles. The increased attention 
on patient compliance and reduction in dose frequency has led to the development of an 
alternative and desirable approach of taking medicine,  other  than oral route for drug 
action, which is to deliver them through the skin [5]. Patients often forget to take their 
medicine, and even the most faithfully compliant get tired of swallowing pills, especially as 
part of daily dosage. 
Skin is one of the most extensive and readily accessible organs of the human body. In 
modern-day pharmaceutical practice, therapeutic compounds are applied to the skin for 
dermatological (within the skin), local (regional) and transdermal (systemic) delivery. For 
transdermal delivery of drugs, stratum corneum is the main barrier layer for permeation of 
drug [7]. So, to circumvent the stratum corneum and to increase the flux through skin 
membrane, different approaches for enhancement of penetration are used. Among others 
things, the skin serves as a port of entry into the body for drug administration to providing 
continuous transdermal infusion into the systemic circulation [8]. As previously mentioned, 
it is one of the most extensive and readily accessible organs of the human body. As both 
the largest and most visible organ of the body, the skin is of unequalled importance in 
portraying an individual’s state of being [9]. The delivery of therapeutic agents to systemic 
circulation via skin requires a delivery mechanism, and many drug delivery mechanisms   Iontophoresis: A Potential Emergence of a Transdermal Drug Delivery System   3 
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utilize alternative forms of energy to facilitate permeation of drugs through the skin. Thus, 
to provide continuous drug infusion through intact skin, transdermal drug delivery system 
(TDDS) has been developed for topical application onto the intact skin surface, which can 
deliver medicines via skin portal to systemic circulation. Delivery via the transdermal route 
is an interesting option in this respect since it is convenient and safe. 
“The transdermal drug delivery system (TDDS) can be defined as a delivery device, which 
upon application on a suitable skin surface will be able to deliver the drug at controlled rate 
into the systemic circulation at clinically sufficient concentrations to ensure therapeutic 
efficacy over a prolonged period of time” [10, 11]. The benefits of using TDDS include 
avoidance of risks and inconveniences of parenteral therapy; improved systemic 
bioavailability which results in avoidance of hepatic “first-pass” effect; and TDDS avoids 
vagaries associated with gastrointestinal absorption due to pH, enzymatic activity, drug-
food interactions, etc. Furthermore, TDDS is useful in achieving the controlled delivery of 
pharmaceuticals, which are relatively small in molecular size and lipophilic in nature. 
However, these systems are rather limited in their capability of achieving the transdermal 
systemic delivery of peptides, proteins and drugs which are  often charged and highly 
hydrophilic in nature.  
TDDS is associated with lacuna of low penetration rate through the outermost layer of the 
skin, the stratum corneum (~20 µm thick), which represents the main contributor to the 
skin’s impermeability. Much effort has been dedicated  to  improving  this impermeability 
[12]. For this purpose, penetration enhancement is the most critical factor in transdermal 
systems, so as to improve flux.  
 
 
Fig. 1.   Schematic representation shows importance of Iontophoresis as penetration 
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Thus, percutaneous absorption is defined as penetration of substance into various layers 
of skin and permeation across the skin into systemic circulation [13]. One of the ways for 
circumventing the stratum corneum barrier includes iontophoresis as shown in Fig. 1. The 
percutaneous absorption is a step wise process which includes [14]: 
1.  Penetration: The entry of a substance into a particular layer. 
2.  Permeation: The penetration from one layer into another, which is different both 
functionally and structurally from the first layer. 
3.  Absorption: The uptake of a substance into systemic circulation.  
Novel Methods in Transdermal Therapeutic Systems 
Newer dosage forms and drug delivery systems providing excellent improvement in drug 
therapy are termed novel drug delivery systems (NDDS). These are termed ‘novel’ 
because of recent development with satisfactory results in the field of drug delivery [15]. 
The primary objective of NDDS is to ensure safety and to improve efficacy of drugs as well 
as patient compliance. Some of these novel advanced transdermal technologies include 
[16] (Fig. 2): 
 
Fig. 2.   Novel advanced transdermal technologies 
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Various technologies other than iontophoresis such as ultrasound, chemical enhancers, 
and  electroporation  have  been  used  for  enhancing  transdermal  drug  transport.  The 
following combinational iontophoresis techniques have been used for TDDS [17]:  
I.  Iontophoresis + Chemicals 
II.  Iontophoresis + Ultrasound; and 
III.  Iontophoresis + Electoporation.  
The limitations associated with chemical enhancers include unsuitability to deliver new bio- 
technological products like peptides, small proteins and oligonucleotides. Hence, the 
renaissance of interest shown toward development of a  new and effective technique, 
iontophoresis, developed over the last decade [18].  
The iontophoretic technique is suitable to improve the transdermal delivery of peptide and 
proteins using a lower current intensity within a short time period. Iontophoresis can be 
defined as “the permeation of ionized drug molecules across biological membranes under 
the influence of electrical current” or a technique that involves the transport of ionic or 
charged molecules into a tissue by the passage of direct or periodic electric current 
through an electrolyte solution containing the ionic molecules to be delivered using an 
appropriate electrode polarity [19]. 
Ions in solution are transferred through the skin by passing DC electrical current between 
two electrodes. Iontophoresis implies the use of a  small amount of physiologically 
acceptable electric current (0.5 mA/cm
2 or less) to drive ionic (charged) drugs into the 
body by using an electrode of the same polarity as the charge on the drug. The drug is 
driven into the skin by electrostatic repulsion. Interposition of moist pad between the 
electrode plate and skin is necessary for making a perfect contact, preventing any skin 
burns, overcoming skin resistance and protecting the skin from absorbing any caustic 
metallic compound formed on the metal plate surface [20]. The technique has been 
observed to enhance the transdermal permeation of ionic drugs by several folds and has 
expanded the horizon of transdermal control drug delivery for systemic medication [21]. 
Beside the usual benefit of TDDS, iontophoresis presents a unique opportunity to provide 
programmed drug delivery. This is because the permeation rate is proportional to the 
current density, which can be readily adjusted. Such dependence on current may also 
make drug absorption via iontophoresis less dependent on biological variables. While all 
these enhancers have been individually shown to enhance transdermal drug transport, 
nowadays their combinations have been hypothesized to be more effective compared to 
each of them alone. 
Historical background of iontophoretic process 
Iontophoresis, derived from the Greek “ionto” meaning ‘ion’ and “phoresis” meaning ‘to 
bear,’ is a process that allows increased penetration of ionized molecule across or into the 
tissue by application of low electric current. Clinical application of current can be traced 
back to the ancient time of the golden age of the Greek civilization and was probably 
originated by Varatti in 1747. 6  V. Dhote et al.:   
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Tab. 1.   Milestones in the field of Iontophoresis 
Milestones  Research 
Glass et al. [22] 
Conducted the most widely quoted research on iontophoresis; 
applied it to multiple joints on a Rhesus monkey then excised the 
underlying tissue to determine depth of penetration. And found that 
therapeutic concentrations of the drug at depths of up to 1.7 cm. 
The vascular network is located just below the layer of skin, 
therefore the drugs can be effectively delivered by this route. 
Stephen et al. [23] 
The first reported study on transdermal iontophoretic delivery of 
insulin for systemic effect was attempted to deliver regular soluble 
insulin to human volunteers. Iontophoresis of commercially available 
insulin was done on eight volunteers, but negative results were 
obtained even after repeating the study on three occasions. 
However, the investigators were able to deliver a highly ionized 
monomeric form of insulin to one pig and observed a decline in 
blood glucose levels and an increase in serum insulin levels. 
Okabe et al. [24] 
Applied new technique for the transdermal delivery of beta-blockers 
and carried out of transdermal permeation of metoprolol in human 
volunteers. No detectable skin damage was observed in the study. 
Wearley & Chien [25] 
Attempted delivery of verapamil, an anti-arrhythmic drug by using 
ionto- phoresis, and concluded that drugs with high systemic toxicity 
have a better safety potential if they are delivered through 
iontophoresis. 
Bhatia and Singh 
[26] 
Investigated the effect of iontophoresis on the in-vitro permeability 
of luteinizing hormone releasing hormone (LHRH) in combination 
with terpine through the porcine skin, which showed a significant 
increase in the flux of LHRH. Extensive research is now going on to 
develop iontophoretic systems for cardiovascular, antianxiety, and 
antidiabetic drugs and for inflammation and pain management. 
Marro and Guy. [27] 
Characterized the perm-selective properties of human and porcine 
skin by using mannitol as a model compound and showed that 
consistent isoelectric points and similar pH dependent selectivity 
observed for human and pigskin. Concluded that the porcine skin is 
an appropriate model for iontophoretic studies and found that 
permeation rate in iontophoresis depends on the dual parameters 
voltage and current density. 
Figueroa et al. [28] 
Demonstrated the in-vitro iontophoretic transdermal permeation of 
methotrexate across pigskin and concluded that the methotrexate 
transport decreases with sodium chloride content and increases 
with increased current density. 
Anderson et al. [29] 
Developed the mechanistic model to describe cathodic 
iontophoresis for both in-vitro and in-vivo studies by using the model 
drug dexamethasone/ dexamethasone phosphate. And reported 
that iontophoresis causes the formation of drug depot within the skin 
due to the exchange of drug ion with chloride ions as the ionic 
current carriers. Concluded that this technique will be suitable for 
the delivery of proteins and enzymes, which are unstable in GI tract.   Iontophoresis: A Potential Emergence of a Transdermal Drug Delivery System   7 
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Tab. 1.   (Cont.) 
Milestones  Research 
Meidan et al. [30]  
Demonstrated iontophoresis and permeation enhancers in 
combination for delivery of Buspirone. And concluded that a 
significant synergistic effect was found between very low-density 
current and permeation enhancer. Also observed that iontophoresis 
at 0.5 mA/cm
2 for 24 h did not affect skin morphology, and the skin 
resistance reverted to its pre-iontophoretic level after 
discontinuation of current. 
Prasad et al. [11] 
Investigated iontophoresis for enhancing the transdermal transport 
of methotrexate by using hydrogel patches. And it was found that 
the transport was influenced by physicochemical properties of the 
system (cross-linking density of the hydrogel and copolymerisation), 
duration of electrical currents and the condition of the skin.  
Sebastiani et al. [31] 
Studied the efficacy of lactic acid as permeation enhancer for drug 
molecules in combination with iontophoresis, and suggested that 
the ionic nature of the enhancer molecules influence the overall 
iontophoretic flux. Lactic acid being anionic agents reduced the 
transport of anionic drug ibuprofen in a concentration dependent 
manner due to co-ionic competition; moreover, the effect of 
association of anodal iontophoresis showed no further 
enhancement.  
Wang et al. [32] 
Investigated the effect of iontophoresis alone and in conjunction 
with other approaches such as chemical enhancement, 
electoporation, sonophoresis and use of micro needles and ion-
exchange materials. These combinations with iontophoresis may 
provide easier and more accurate delivery of macromolecules and 
poorly water-soluble compounds. 
Mutalik et al.[33] 
Developed a membrane-controlled iontophoretic delivery of 
Glibenclamide, and showed that membrane controlled system 
exhibited better control of hyperglycemia and more effectively 
reversed the diabetes mellitus complications than oral glibenclamide 
administration in mice. 
Mutalik et al.[34] 
Developed a ‘Membrane-moderated system’ for delivery of Glipizide 
and found that this system negligibly causes skin irritation and 
resulted in better control of diabetes as compared to oral 
administration. 
Mutalik et al. [35] 
Developed the matrix patch system for Glipizide delivery. Results of 
the in-vivo studies showed the patches are more effective than oral 
formulation on chronic application. 
Kolli et al. [36] 
Investigated the microneedle (MN) mediated in vitro transdermal 
iontophoretic delivery of prochlorperazine edisylate (PE) across 
dermatomed human skin. Application of iontophoresis in conjunction 
with microneedle pre-treatment resulted in an enhanced flux of 
drug. 
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Tab. 1.   (Cont.) 
Milestones  Research 
Nair et al. [37] 
Reported utilization of chemical penetration enhancers in 
conjunction with iontophoresis is regarded as the most effective 
method to enhance the passage of molecules across the skin 
barrier. A systematic approach to enhance the transdermal delivery 
of metoprolol tartrate and the subsequent release of the drug depot 
in the skin was investigated. 
Takasuga et al. [38] 
Investigated feasibility of transdermal delivery of tramadol, a 
centrally acting analgesic, by anodal iontophoresis using Ag/AgCl 
electrodes by in vitro and in vivo studies. The study reveals that 
anodal iontophoresis provides current-controlled transdermal 
delivery of tramadol without significant interspecies differences, and 
enables the delivery of therapeutic amounts of tramadol. 
 
The idea of applying electric current to increase the permeation of electrically charged 
drugs into surface tissues was probably originated by Pivati in 1747. In the eighteenth 
century Galvani and Vota combined the knowledge that electricity can move different 
metal ions and the movement of the ions produce electricity. In beginning of twentieth 
century Leduc introduced  the term ionototherapy and formulated laws regarding this 
process. Furthermore, many researchers have contributed to the field of iontophoresis with 
great success, and some of them are represented in Table 1. 
Iontophoretic Research & Drug Delivery 
Since most of the drugs showed less than adequate skin permeability in passive studies, 
iontophoresis was proposed to be a physical technique for enhancement of skin 
permeation. The release characteristics of drug from delivery system and the composition 
of drug delivery system can largely affect the transdermal permeation of drug molecules 
[39–41]. Organic solvents and surface active agents can also alter the permeability of skin 
and enhance the percutaneous absorption. The transdermal permeation rate increases as 
the drug release rate from the drug delivery system increases. Major mechanisms of 
enhancing drug flux through skin are: 
•  Iontophoresis (electrorepulsion, electromigration or Nernst plank effect) 
•  Electroosmotic flow 
•  Damage effect (current induced increase in skin permeation) 
Iontophoresis enhances drug delivery across the skin by two principal mechanisms: 
electrorepulsion and electroosmosis. Electrorepulsion is the direct effect of the applied 
electric ﬁeld on a charged permeant. The second mechanism, electroosmosis, results from 
the fact that the skin supports a net negative charge at physiological pH [42, 43].  
Iontophoresis is a non invasive method used to boost high concentration of a charged 
substance, generally medication or bioactive agents, transdermally by repulsive electro-  Iontophoresis: A Potential Emergence of a Transdermal Drug Delivery System   9 
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motive  force  using  a  small electrical  current  applied  to  an  iontophoretic  chamber 
containing a similarly charged active agent and its vehicle.  
For effective delivery via iontophoresis, the positively charged chamber, termed anode, will 
repel a positively charged chemical, while the negatively charged cathode, will repel a 
negatively charged chemical into the skin. In the presence of an electric field, electro-
migration and electroosmosis are the dominant forces in mass transport [44].  
These movements are measured in units of chemical flux, commonly µmol/cm
2 h. This 
technique is based on the general principle that like charges repel each other. Thus, 
during iontophoresis, if delivery of a positively charged drug (D
+) is desired, the charged 
drug is dissolved in the electrolyte surrounding the electrode of similar polarity, i.e. the 
anode in this example [45]. On application of an electromotive force the drug gets repelled 
and moves across the stratum corneum towards the cathode, which is placed elsewhere 
on the body. Communication between the electrodes along the surface of the skin has 
been shown to be negligible, i.e. movement of the drug ions between the electrodes 
occurs through the skin and not on the surface. When the cathode is placed in the donor 
compartment of a Franz diffusion cell to enhance the flux of an anion, it is termed cathodal 
iontophoresis, and for anodal iontophoresis the situation would be reversed. Iontophoresis 
uses a low current, and patients’ have little or no sensation during the procedure [8].  
 
Fig. 3.   Diagram of iontophoretic technique: as current is applied the drug cations are 
repelled and move through the skin and eventually they are absorbed in the 
systemic circulation. 
The basic mechanisms of ionic/molecular transport across the skin by iontophoresis is 
illustrated in figure 3. Like charges repel each other, hence the charged ion is repelled by a 
similarly charged electrode and absorbed through the skin. The  skin being negatively 
charged at physiological pH acts as a cation selective membrane and favours movement 
of cations through anodal iontophoresis. Anodal iontophoresis also causes convective 
motion of the solvent occurring in response to movement of counter ions. This process of 
electroosmosis is involved in the motion of neutral compounds as well as positively 
charged ions. Because of the complex nature of iontophoretic delivery, a number of 
attempts have been made to define the rate of iontophoretic delivery. 
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Abramson and Gorin derived an equation to compare the iontophoresis flux to electric 
mobility, electroosmosis  and simple  diffusion. The increased flux during iontophoresis 
would include [29]. 
•  Flux due to the electrochemical potential gradient across the skin;  
•  Change in the skin permeability due to the electric field applied; and  
•  Electro-osmotic water flow and the resultant solvent drag. 
J
ionto = J
electric +J
passive + J
convective 
J
electric…The flux due to electric current application;  
J
passive…The flux due to passive delivery through the skin; and  
J
convective…The flux due to convective transport due to electro osmosis.  
The Nernst-Planck equation has been used with modifications to predict iontophoretic 
enhancement ratios (ratio of steady state flux in presence of electric potential and in 
absence of potential) as the original equation lacks a term for convective electroosmotic 
flow  [46–48]  studied the contributions of osmotic flow and incorporated this fact into 
several equations. 
Pathways of Molecular Transport in Iontophoresis 
Percutaneous absorption may take effect simultaneously by three main pathways [49, 50] 
(Fig. 4.): 
•  Intercellular (paracellular) between the comeocytes;  
•  Transcellular (intracellular) through cells;  
•  Appendageal (shunt pathway) hair follicles,  sweat ducts, secretary glands.   
 
 
Fig. 4.   Pathways of molecular transport in iontophoresis 
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Ions prefer the routes of shunt pathway. Physiochemical properties of drug molecules 
affect the drug distribution. Hydrophilic molecules tend to localize the drug in hair follicles. 
On the other hand, lipophilic molecules are distributed mostly in lipid intercellular regions 
of the lipid membrane of epidermal keratinocytes and stratum corneum. Therefore, 
Transdermal iontophoresis should be termed as electrically assisted transdermal delivery. 
Electroosmotic flow is a flux or bulk fluid induced by a voltage difference across a charged 
membrane; it is a one way flow of counter ions i.e. from anode to cathode. Therefore, 
cathodic delivery of anions is hindered, and thus anodic delivery of cations is assisted by 
it. When the delivery of large anion from the anodic compartment is more efficient than 
delivery from cathode, this is calledwrong-way iontophoresis. The electrorepulsion effect 
gives the largest enhancement to flux of small lipophilic cations [51]. 
Iontophoresis as drug delivery module 
The potential of this technique has been exploited for the transdermal delivery of many 
drugs with poor penetration properties e.g., high molecular weight electrolytes such as 
proteins, peptides and oligonucleotides which are normally difficult to administer except 
through parenteral route. It also offers a great potential for the delivery of charged peptides 
used as drugs. Although iontophoresis has been able to achieve significant increase in the 
transdermal absorption of many drugs, it has not been able to show significant permeation 
of larger peptides like insulin [52]. 
An iontophoretic drug delivery system has these basic components: 
•  An energy source of electronic current, which usually consists of a battery and 
controlled electronics;  
•  An active reservoir, which contains the ionic therapeutic agent; and  
•  An indifferent or return reservoir system, which contains an electrolyte and serves 
to complete the electric circuit. 
•  Also a control system, to monitor the overall process. 
 
Fig. 5.   Schematic representation of iontophoretic system 
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When the active and indifferent reservoir systems are placed on the skin, the current 
source causes electronic current to flow to the active reservoir where the electronic current 
is transformed into ionic current. The ionic current flows through the active reservoir, 
through the skin, beneath the skin towards the indifferent reservoir, and back through the 
skin into the indifferent reservoir. At the indifferent reservoir, it is transformed back into 
electronic current, completing the circuit at the opposite pole of the current source [53, 54] 
(Fig. 5).  
 
Fig. 6.   Factors Affecting Iontophoretic Delivery System 
Factors Affecting Iontophoresis Transport System 
Human skin is not all the same. There are numerous differences among patient groups as 
well as between various regions of the body, age and ethnicity. Various factors have been 
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systemic and underlying tissue solute absorption. Blood supply, however, does not appear 
to affect the drug penetration fluxes through the epidermis during iontophoretic delivery. 
Cross and Roberts showed that solute in the upper layer of the skin following 
iontophoresis was comparable in anaesthetized rats and sacrificed rats. It can thus be 
presumed that the blood did not affect the penetration through the epidermis since the 
latter has no blood supply [17, 57]. Condition of skin also affects the penetrating properties 
of permeant. Roberts et al., studied the in-vivo passive diffusion of methyl salicylate using 
skin from different areas of  the  human  body and observed the following rank order: 
abdomen > forearm > instep > heel > planter, for all subjects. 
Duration  and  intensity  of  current used depends on the sensitivity of  the  patient.  It  is 
desirable to increase the current slowly and to remain at a predetermined level as long as 
the treatment required, following which the current is slowly decreased to zero [28].The 
time for iontophoresis ideally is 1 minute for the increasing phase and 30 seconds for the 
decreasing phase. The intensity of current used is between 40mA to 10mA regulated with 
a 2500 Ω potentiometer. Current ranging from 5 to 10mA has been found to be painless. 
A major drawback of transdermal delivery systems is the potential for localized irritant and 
allergic cutaneous reactions. At the earlier stages of formulation development, it is, 
therefore, important to evaluate both drugs and excipients for their potential to cause 
irritation and sensitization [59, 60]. 
These systems are largely dependent on the ranges of parameters which affect the 
performance of system and such factors need to be considered (Tab. 2.) [45, 60, 61]. 
Tab. 2.   Optimum levels of parameters affecting iontophoretic systems 
Parameter  Optimum 
range  Above range  Below range 
Inﬂuence of pH  pH 5.5 and 
below 
Increasing risk for 
vascular reaction 
The concentration of hydrogen 
ion increases and a vascular 
reaction (vasodilatation) is 
initiated because of C-fibre 
activation. 
Current strength 
1 mA not 
more than 3 
min 
Risk of non speciﬁc 
vascular reactions 
(vasodilatation) 
increases. 
No resultant. 
Current density  3–5 mA 
Risk for unspecific 
electrically mediated 
vasodilatation 
No resultant. 
Molecular size 
and molecular 
weight 
smaller and 
hydrophilic 
The permeability 
coefficient decreases  Non specific transport. 
Ionic strength & 
presence of 
other ions 
— 
Decrease drug delivery, 
as extraneous ions 
compete with the drug 
ions. 
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Types of Iontophoretic System [62, 63] 
The system of drug delivery via iontophoresis can be classified  in accordance to the 
modification and improvement done in this system which allows the uniform and predictive 
drug release in an effective manner (Fig. 7). 
 
Fig. 7.   Various types of iontophoretic system 
Reverse iontophoresis 
Reverse  iontophoresis, a  technique  in which  low  electric current is applied to draw 
intestinal fluid through the skin, is widely  applied  these  days  in  devices meant  for 
diagnostic application. This provides a convenient and non-invasive method for sampling 
of body fluids so as to permit simultaneous measurement of the desired substance in the 
body fluid and thus to monitor them efficiently. The reverse iontophoretic process applies 
to continuously monitor the glucose level in the blood for e.g. Glucowatch®, which is a 
system that provides a needleless means of monitoring blood glucose levels in diabetic 
patients and uses an electrical signal which is proportional to the amount of glucose in the 
extracellular fluid. This provides a feasible method for rapid, linear extraction of 
phenylalanine and for easy detection (by instruments like biosensors) of monitoring 
diseases like phenylketonuria. This technique not only provides non-invasive sampling but 
also provides filtered samples free from large molecules with ease of operation. However, 
this technique is useful for less tedious sampling. For it to be successful, it needs a very 
sensitive  analytical method  since  the  amount  extracted is very low. For e.g. Caffeine, 
theophyline; lithium; phenytoin are successfully tried using this approach. 
Pulsatile/switching iontophoresis  
Many studies have been conducted where instead of using constant DC iontophoresis, DC 
in the form of short pulses have been used [63]. 
Iontophoresis and electoporation combination 
Iontophoresis can also be combined with other skin penetration enhancing techniques like 
electoporation, which involves the application of high voltage (> 100 V) pulses for short 
duration (µs-ms) to increase the permeability through the skin. Electoporation is applied 
before iontophoresis, which causes the creation of permeablized skin because of exposure 
to high pulses voltage [64]. Thus, when applied after electoporation, iontophoresis helps in 
extending  the permeablized state of the skin,  resulting in the rapid onset (which is a 
drawback of iontophoresis  alone)  and  sometimes  increased  flux  [65]. The  increased 
Pulsative/switching 
Iontophoresis 
Reverse 
iontophoresis 
Iontophoresis and 
electoporation combination 
 
Iontophore
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transport  by  electoporation  caused  by  creation  of  electro pores  as well  as  local field 
induced electrophoretic drift. Fang et al.,  studied the effect of electoporation on the 
delivery of buprenorphine and showed that on application of 300 V or 500 V pulses 
increased the buprenorphine flux by several folds over passive transport of it; e.g. drugs 
like Salmon calcitonin (SCT) and PTH combination; Tacrine hydrochloride have been 
successfully tried using this approach [66].  
Selection Criteria for Drug Candidate 
Transdermal route of drug administration has certain inherent difficulties that make it 
unsuitable for a  large number of drugs. The selection of suitable  candidates is an 
important step for success of transdermal research [27, 56, 60, 67, 68]. 
Ideal characteristic drug should possess for the successful delivery through this approach: 
•  A TDDS should not cover an area more than 50 cm
2 and the daily dose is of order 
of a few mg. 
•  The effective concentration of the drug should be low, presumably in the ng/ml.  
•  The half life (t1/2) of the drug should be short. 
•  The active ingredients should not cause any skin toxicity or irritation. 
•  As the diffusion of drug through polymer as well as skin is dependent on molecular 
size, the drug of low molecular size is preferred. 
•  The drug should have a low melting point so that it acts on normal body 
temperature.  
•  Drugs, which degrade in the GI tract or/are inactivated by hepatic first-pass effect, 
are suitable candidates for transdermal delivery. 
•  Tolerance to the drug must not develop under the near zero-order release profile of 
transdermal delivery. 
•  The candidate drug should have adequate hydrophilic and lipophilic balance to 
negotiate the lipid barrier of stratum corneum before being partitioned into the 
aqueous viable tissue. 
Every system has certain benefits and shortcomings which makes it difficult to fulfill the 
required goal and provide the desired results in optimum conditions (Tab. 3). 
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Tab. 3.   Merits and demerits of transdermal iontophoretic system [60, 61, 69, 70] 
Merits 
It is a non-invasive technique that could serve as a substitute for chemical 
enhancers. 
It eliminates problems like toxicity problems, adverse reaction formulation problems 
associated with presence of chemical enhancers in pharmaceuticals. 
It may permit lower quantities of drug compared to use in TDDS, and this may lead 
to fewer side effects. 
TDDS of many ionized drugs at therapeutic levels was precluded by their slow rate 
of diffusion under a concentration graduation, but iontophoresis enhanced flux of 
ionic drugs across skin under electrical potential gradient. 
Eliminate the chance of over or under dosing by continuous delivery of drug 
programmed at the required therapeutic rate. 
Permit a rapid termination of the modification, simply by stopping drug input from 
the iontophoretic delivery system. 
Self-administration is possible. 
Iontophoresis turned over control of local anesthesia delivery in reducing the pain of 
needle insertion for local anesthesia. 
Demerits 
Arrangement to protect electric shock needed.  
An excessive current density usually results in pain. 
Burns may be caused by electrolyte changes within the tissues. 
Ionic form of drug in sufficient concentration is necessary for iontophoretic delivery. 
Treatment is somewhat costly. 
  
Recent efforts in this technology have resulted in the design of electrodes, which avoids 
burns. This technique has gained acceptance for local therapy. Its application for systemic 
medication would require further research to elucidate an easy approach to drug delivery. 
The development of iontophoresis can explore and has widened the scope of transdermal 
delivery to the absorption of poorly absorbed ionic drugs [71–73]. There is a wide variety of 
drugs that has been investigated and reported recently for iontophoretic delivery (Tab. 4). 
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Tab. 4.   List of Drugs Investigated Recently for Iontophoretic Delivery 
Drug  Animal/membrane 
model Used 
Experimental 
conditions  Results 
Arginine & 
Vasopressin 
(AVP) [73] 
Rat skin 
In vitro: Franz diffusion 
cell; Ionic strength: 
0.05M and 0.5M; 
Current: 0.5 mA/cm
2; 
Time: 4h. Studied the 
effect of ionic strength 
Enhancement ratio 
was found to be 6 
folds at 0.5 M 
compared to 0.05 M 
ionic strength 
Atenolol 
hydrochloride [74] 
Porcine buccal 
mucosa 
In vitro: Horizontal 
three chamber 
permeation cell; 
Current densities: 0.1, 
0.2, 0.3, 0.4 mA/cm
2; 
Time: 8h Studied the 
effect of donor 
concentration. 
Delivery of atenolol 
hydrochloride 
increased with 
increase in donor 
concentration 
Buprenorphine 
[75] 
Human epidermal 
membrane 
In vitro: Franz (vertica) 
diffusion cell. 0.5 
mA/cm
2; Time: 4h. 
An 8 fold increase in 
delivery by anode 
than cathode 
Chlorhexidine 
dihydrochloride 
[96] 
Excised human skin 
In vitro: Side by side 
diffusion cell; Constant 
iontophoresis for 1h; 
0.5 mA/cm
2 
Cumulative amount of 
drug permeated 
showed a 7 times 
increase in drug flux 
by iontophoresis 
Diclofenac [48]  Guinea Pigskin 
In vitro: Current: 0.2 
and 0.5 mA/cm
2; Time: 
6 h. Studied the effect 
of current on drug 
delivery. 
Full plasma 
concentration 
achieved in 1 h. Drug 
delivery was 
proportional to current 
(371± 141 µgm / it at 
0.5 mA/cm
2 and 132 ± 
62 µ gm/ lt at 0.2 mA/ 
cm
2). 
Gentamycin [76]  White rabbits  In vivo: 1 mA; Time: 60 
sec. 
Concentration 
achieved in cornea 
and aqueous humour 
was 12–15 times 
higher than the topical 
eye drop. 
Leuprolide 
(LHRH agonist) 
[77] 
Human epidermal 
skin 
In vitro: Conducted 
using buffers with pH: 
4.5 and pH: 7.2; 
Current: 0.5–2.3 
mA/cm
2 
Iontophoretic 
permeation was found 
to be double at pH: 
7.2 than at pH: 4.5 
(increased 
transference number 
was observed). 18  V. Dhote et al.:   
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Tab. 4.   (Cont). 
Drug  Animal/membrane 
model Used 
Experimental 
conditions  Results 
Nalbuphine (Nb) 
and prodrug 
Nalbuphine 
pivalate, 
decanoate and 
enduthate. [78] 
Intact skin, stratum 
corneum stripped 
skin, dilipidised skin, 
wistar rat skin. 
In vitro: Done to 
assess the effect of 
prodrug lipophilicity on 
passive and 
iontophoretic 
permeation. 
Enhancement ratio 
highest for Nb and 
decreased as the 
lipophilicity of the 
prodrug increased. 
Piroxicam [79] 
Ventral forearm 
surface of human 
volunteer 
In vivo: Two glass 
chambers; Current-0.3 
mA/cm
2 applied via 
phoresor II (tape 
stripped stratum 
corneum) 
10 fold increased 
permeation. 
Rotigotine [80]  Human stratum 
corneum 
In vitro: Side-by-side 
diffusion cell; Studied 
the effect of drug 
concentration and 
effect of co-ions 
triethylamine (TEA) 
and tributylamine 
(TBA) on flux; 0.05mA/ 
cm
2 
Flux increased with 
drug concentration. 
With co-ions viz. TEA, 
flux of rotigotine 
increased while TBA 
showed no effect on 
flux. 
Salbutamol [81]  Non rate limiting 
artificial membrane 
In vitro: Release of 
drug from a liquid 
crystalline vehicle was 
studied. 
Enhanced flux from 
the vehicle. 
Thiocolchicoside 
[82] 
Rabbit and human 
skin 
In vitro: Glass-Franz 
type cell. 
Enhanced flux of the 
drug over passive 
control. 
Timolol maleate 
(TM) [83] 
Excised rat, rabbit, 
guinea pig, mouse 
and human skin. 
In vitro: Valia- Chien 
side by side diffusion 
cell. Studied the effect 
of species. 
Iontophoretic transport 
highest in human skin 
and lowest in rabbits. 
 
Iontophoretic delivery of peptides and proteins 
Transdermal delivery has been at the forefront of research addressing the development of 
non-invasive methods for the systemic administration of peptide and protein therapeutics 
generated by the biotechnology revolution [16, 39, 84]. Various approaches showed 
potential to cross the skin’s formidable barrier function. Among them iontophoresis 
transiently increases the skin permeability of peptides and proteins [85, 86].  
Peptides and proteins play a determined role in modern therapy. Their potency and 
specificity make them excellent therapeutic agents; however, their physicochemical 
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subcutaneous, intramuscular or intravenous injection [87]. These act as effector agents 
that regulate and/or mediate physiological processes, serving as hormones, neuro-
transmitters and signal transducing factors. Transdermal iontophoresis enables hydrophilic 
charged molecules to be administered through the skin in an effective, non-invasive, 
patient-friendly manner [88]. Controlled non-invasive administration using more patient-
friendly advanced delivery technologies may combine the precision afforded by parenteral 
administration with improved compliance and the potential for individualized therapy 
[16, 39]. It has long been known that iontophoresis can administer therapeutic amounts of 
biologically active peptides into the body. More recent studies have shown that it is also 
capable of delivering structurally intact, functional proteins non-invasively into and across 
intact human skin [43] and becomes the most popular choice of drug delivery. 
Clinical Applications of Iontophoresis in Other Disciplines [89–91] 
Dentistry 
Dentistry, probably to an even greater extent than physical therapy, has used 
iontophoresis with patients prior to oral surgical procedures. [22]. 
1.  Treatment of hypersensitive dentin (e.g. in teeth sensitive to air and cold liquids) 
using negatively charged fluoride ions;  
2.  Treatment of oral ulcers ("canker sores”) and herpes orolabialis lesions ("fever 
blisters") using negatively charged corticosteroids and antiviral drugs, respectively; 
and  
3.  The application of local anaesthetics to produce profound topical anaesthesia, as is 
done in some physical therapy applications. 
Dermatology 
Iontophoresis has many uses in the field of dermatology. Except for the use of lidocaine for 
anaesthesia and the treatment of patients with hyperhidrosis, most uses of iontophoresis 
in dermatology have largely been abandoned. Iontophoresis with tap water or 
anticholinergic compounds has been used for the treatment of patients with hyperhidrosis 
of the palms, feet, and axillae [91]. 
Otorhinolaryngology 
Iontophoresis is a preferred method for obtaining anaesthesia of the tympanic membrane 
prior to simple surgical procedures involving that structure. Iontophoresis of zinc has also 
been used for the treatment of patients with allergic rhinitis. 
Ophthalmology 
Iontophoresis has been used experimentally to deliver antibiotics into the eye. The 
principal disadvantage of this technique is the time required for direct contact of the 
electrode with the eye.  
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Diagnostic Applications  
Iontophoretic application of the drug  pilocarpine  produces intense sweating, allowing 
sufficient amounts of sweat to be collected and analyzed. This is now accepted as the 
primary test in the diagnosis of cystic fibrosis. 
Conclusion 
Considerations that are important for design and development of pharmaceutical products 
intended for application to the skin require an ideal skin penetration enhancer, for which 
continual research has occured  over a number of decades.  Although many potent 
enhancers have been discovered, their clinical application has been limited because of 
their toxic side effects. However, the recent approaches for penetration enhancement do 
not  compromise  skin  barrier function  as  do  chemical  and  physical penetration 
enhancement technique, and hence iontophoresis (as a physical enhancement technique) 
can serve as the better alternative. As previously defined, iontophoresis is the technique 
which facilitates the movement of ions across a membrane under the influence of an 
externally applied electrical potential difference. Iontophoresis dramatically enhances both 
the rate of release and the extent of penetration of the salt form of the drugs. Without 
iontophoresis, such charged species are largely incapable of transdermal penetration due 
to the skin's lipophilic nature. Iontophoresis is gaining wide popularity as it provides a non 
invasive and convenient means of systemic administration of drugs with poor 
bioavailability profile, short half life and with multiple dosing schedules. Iontophoresis, in 
comparison to oral route, definitely provides benefits of improved efficacy and/or reduces 
adverse effects. 
Transdermal Technology ensures as much as 95% of a supplement reaches the cells 
where it is needed.  Doctors around the world are calling Transdermal delivery "The 
delivery system of the future" and found fantastic alternative to pills and tablets. The 
iontophoretic delivery of macro-molecules allows the strategy for non‐invasive transdermal 
delivery of peptide‐based pharmaceuticals, and contributes to further future advancement 
toward recombinant DNA technology. Although iontophoresis provides many benefits and 
seems to be more effective than other techniques, there is a need for further research and 
judicious use of technology with microelectronics devices and to make it available for 
commercial application. Thus, iontophoresis may prove to be “a potential emergence to 
transdermal drug delivery”. 
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